NIAID conducts and supports research to better understand, treat, and ultimately prevent infectious and immune-mediated diseases. For more than 60 years, NIAID research has led to new therapies, vaccines, diagnostic tests, and other technologies that have improved the health of millions of people in the United States and abroad. This page highlights notable scientific advances made by NIAID laboratories and NIAID-funded researchers.
NIAID Research Journeys
Explore the stories behind how NIAID-funded basic and clinical research paved the way for the development of important therapeutics and vaccines.
NIH-funded research helped pave the way for development of Teplizumab, the first FDA-approved therapeutic for delaying type 1 diabetes (T1D) onset in at-risk patients. This delay reduces the potential for severe long-term complications in patients, thereby improving their quality of life.
NIAID-funded basic and clinical studies helped establish the fundamental knowledge necessary for the private sector to develop protein vaccines. These vaccines are safe and effective at preventing severe RSV in some target populations.
Accomplishments Over the Years
In 2020, NIAID and its global partners rapidly leveraged their scientific infrastructure and expertise to conduct critical basic, preclinical, and clinical research to address the coronavirus disease 2019 (COVID-19) pandemic. Although considerable challenges remain, scientists have made enormous strides this year in understanding, preventing, and treating COVID-19. Other research brought us closer to a new option for HIV prevention, a shorter treatment regimen for drug-susceptible tuberculosis, and a potential new eczema treatment, among many other advances.
In 2019, research at NIAID and NIAID-funded institutions accelerated progress toward development of a universal flu vaccine, enhanced knowledge of organ transplantation among people with HIV, and provided new tools for studying human prion diseases. Scientists also made advances in treating Ebola, developing gene therapy for a rare immunologic disorder, and understanding the causes of acute flaccid myelitis. In addition, NIAID made strides toward ending the HIV epidemic in the United States and preventing tuberculosis.